- Home
- TCBI vs AKRO Comparison
TCBI vs AKRO Comparison
Compare TCBI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBI | AKRO |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TCBI | AKRO |
|---|---|---|
| Price | $90.34 | $54.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $87.50 | $73.56 |
| AVG Volume (30 Days) | 430.9K | ★ 1.4M |
| Earning Date | 10-22-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2948.16 | N/A |
| EPS | ★ 6.10 | N/A |
| Revenue | ★ $1,149,977,000.00 | N/A |
| Revenue This Year | $47.92 | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | $14.79 | ★ N/A |
| Revenue Growth | ★ 39.14 | N/A |
| 52 Week Low | $59.37 | $21.34 |
| 52 Week High | $94.61 | $58.40 |
Technical Indicators
Market Signals| Indicator | TCBI | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 67.61 |
| Support Level | $82.15 | $54.22 |
| Resistance Level | $92.16 | $54.41 |
| Average True Range (ATR) | 2.33 | 0.14 |
| MACD | 0.58 | -0.17 |
| Stochastic Oscillator | 81.97 | 80.95 |
Price Performance
Historical ComparisonAbout TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.